drugset / Trial / NCT00243724

HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related Disease

NCT00243724

Phase 3 Completed 350 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

Determine if different levels of acid-suppression with esomeprazole for 6 months on chosen histological markers of esophageal epithelial acid-related disease in patients with upper GI symptoms.

Timeline

Start
2005-04
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule